Non-genomic estrogen regulation of ion transport and airway surface liquid dynamics in cystic fibrosis bronchial epithelium by Saint-Criq V et al.
Non-Genomic Estrogen Regulation of Ion Transport and
Airway Surface Liquid Dynamics in Cystic Fibrosis
Bronchial Epithelium
Vinciane Saint-Criq1, Sung Hoon Kim2, John A. Katzenellenbogen2, Brian J. Harvey1*
1Molecular Medicine Department, Royal College of Surgeons in Ireland, Beaumont Hospital, Dublin, Ireland, 2Department of Chemistry, University of Illinois at Urbana-
Champaign, Urbana, Illinois, United States of America
Abstract
Male cystic fibrosis (CF) patients survive longer than females and lung exacerbations in CF females vary during the estrous
cycle. Estrogen has been reported to reduce the height of the airway surface liquid (ASL) in female CF bronchial epithelium.
Here we investigated the effect of 17b-estradiol on the airway surface liquid height and ion transport in normal (NuLi-1) and
CF (CuFi-1) bronchial epithelial monolayers. Live cell imaging using confocal microscopy revealed that airway surface liquid
height was significantly higher in the non-CF cells compared to the CF cells. 17b-estradiol (0.1–10 nM) reduced the airway
surface liquid height in non-CF and CF cells after 30 min treatment. Treatment with the nuclear-impeded Estrogen
Dendrimer Conjugate mimicked the effect of free estrogen by reducing significantly the airway surface liquid height in CF
and non-CF cells. Inhibition of chloride transport or basolateral potassium recycling decreased the airway surface liquid
height and 17b-estradiol had no additive effect in the presence of these ion transporter inhibitors. 17b-estradiol decreased
bumetanide-sensitive transepithelial short-circuit current in non-CF cells and prevented the forskolin-induced increase in
ASL height. 17b-estradiol stimulated an amiloride-sensitive transepithelial current and increased ouabain-sensitive
basolateral short-circuit current in CF cells. 17b-estradiol increased PKCd activity in CF and non-CF cells. These results
demonstrate that estrogen dehydrates CF and non-CF ASL, and these responses to 17b-estradiol are non-genomic rather
than involving the classical nuclear estrogen receptor pathway. 17b-estradiol acts on the airway surface liquid by inhibiting
cAMP-mediated chloride secretion in non-CF cells and increasing sodium absorption via the stimulation of PKCd, ENaC and
the Na+/K+ATPase in CF cells.
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Introduction
17b-estradiol (E2) is the most potent circulating estrogen
hormone during the reproductive years of women. Beyond its
role in reproduction and during the menstrual cycle, it has been
shown to modulate many physiological processes such as cell
proliferation, apoptosis, inflammation and ion transport in many
tissues. Estrogen targets ion transport in different ways, including
the control of channels mRNA and protein expression, surface
abundance, degradation and activity (conductance).
In the kidney, estrogen regulates protein expression of the Na+-
K+-2Cl2 cotransporter (NKCC2) that regulates sodium transport
along the thick ascending limb of Henle’s loop [1]. E2 inhibits
Na+-Pi cotransport across renal brush border membranes from
ovariectomized rats [2], induces a rise in cytosolic Ca2+
concentration [3] and regulates the Mg2+ channel TRPM6 [4,5]
and Ca2+ channel TRPV5 [6]. Estrogen also modulates intestinal
epithelial Cl2 transport [7,8,9]. In distal colonic cells, physiolog-
ical concentrations of estrogen increase intracellular Ca2+
concentration [10,11] and activate c-AMP dependent protein
kinase (PKA) and protein kinase C (PKC) [12]. These kinases
associate with and inhibit the potassium channel KCNQ1 and
[13]. Potassium recycling via KCNQ1 channels at the basolateral
plasma membrane provides the driving force for chloride secretion
at the apical plasma membrane. Therefore, in distal colonic cells
estrogen inhibition of KCNQ1 activity leads to the inhibition of
transepithelial chloride secretion. Furthermore, in the T84
epithelial cell line, inhibition of forskolin induced Cl2 secretion
by supra-physiological concentrations of E2 appeared to result
from a direct interaction with the Cl2 channel Cystic Fibrosis
Transmembrane conductance Regulator (CFTR) protein [14].
The role of E2 in lung physiology and pathophysiology is poorly
understood although in the airways, female gender enhances the
risk of worse prognosis in pulmonary diseases such as asthma,
chronic obstructive pulmonary disease or cystic fibrosis [15].
Cystic Fibrosis (CF) is the most frequent recessive disease in
Caucasian populations and is caused by mutations in the CFTR
gene leading to the absence or the lack of function of this ABC
transporter-class ion channel, which transports chloride and
bicarbonate. This disease affects many organs that produce
exocrine secretions, but the foremost cause of morbidity and
mortality is the lung pathology. In normal airways, the epithelium
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is covered by an aqueous film termed the Airway Surface Liquid
(ASL) composed by the periciliary layer in which cilia beat to
remove inhaled particles and pathogens trapped in the mucus
layer. In CF, the ASL layer height is reduced below 7 mm, which
compromises the efficiency of mucociliary clearance. This height
of 7 mm is critical for an efficient mucociliary clearance as it is the
approximate height of outstretched cilia and it has been shown
that a height below 7 mm reduces mucociliary clearance [16].
Significant differences have been reported in the progression of CF
in male and female patients and are termed ‘‘the CF gender gap’’.
Lung function among female patients deteriorates 26% more
rapidly than in male patients, and on average male patients survive
9 years longer than females [17,18]. This points to an endocrine
involvement in the regulation of the processes that impact on CF
severity.
Recently, Coakley et al. showed that E2 reduced significantly
ASL height and that UTP-mediated Cl2 secretion is decreased in
bronchial epithelium from CF and non-CF women during the
period of high blood estrogen levels. This effect involves the
inhibition of Ca2+ signalling, possibly through the binding of E2 to
the Estrogen Receptor ERa but not ERb [19]. In isolated alveolar
epithelial cells from rat foetuses, E2 and progesterone increased
ENaC and Na+/K+ATPase activities after 48 to 72 hours of
treatment. This effect involved the stimulated expression of a- and
b-ENaC and Na+/K+ATPase-b1 mRNA [20].
Besides modulating ion transport in the airways, E2 has been
shown to influence the immune response in CF airways. Estrogen
exerts differential effects on inflammation processes. In CF female
bronchial epithelium, E2 decreases IL-8 secretion through ERb
modulation of secretory leucoprotease inhibitor and NF-kB
signalling pathways, providing a propitious environment for
infection and colonization [21]. In CF, female gender is also a
risk factor for the development of mucoid Pseudomonas aeruginosa
[22]. Studies on wild type and CFTR2/2 mice showed that female
mice displayed much higher susceptibility to P. aeruginosa lung
infection than males, (i.e., higher weight loss, number of bacteria
remaining in the lungs, mortality) [23]. Moreover, CF male mice
treated with estrogen showed an aggravation of P. aeruginosa,
induced pneumonia, an up-regulation of the immune adaptative
Th17 response and a decrease in the innate antibacterial immune
response compared to untreated CF male mice [24].
From these studies it appears that estrogen is deleterious to CF
female lung function and that the deterioration of the CF
condition seen in girls at puberty is due to an elevation of estrogen
levels in the body. However, the molecular mechanisms and ion
transporter targets for estrogen in airway epithelium are unknown.
In this study we uncover an anti-secretory and pro-absortive effect
of estrogen in non-CF and CF airway epithelia, respectively. These
responses occur via inhibition of Cl2 transport and K+ recycling
(anti-secretion in non-CF) and stimulation of ENaC and Na+/K+
ATPase (in CF) that decrease ASL hydration in both cell types.
These ion transporter and ASL responses to estrogen occur as a
non-genomic effect via ERa and may underlie estrogen effects in
vivo to exacerbate lung function especially in CF, when secretion is
already compromised through the lack of functional CFTR.
Materials and Methods
Ethics statement
Ethical approval, for the use of primary tissue obtained from
bronchoscopy, was granted by Our Lady’s Children Hospital
Crumlin research ethics committee and full written informed
consent was obtained from the parents of all participating subjects.
CF children were excluded from this study if they were taking
leukotriene receptor antagonists or treatment dose with antibiotics
in the two weeks prior to bronchoscopy. Primary cells were
obtained from bronchial brushings obtained in 3 children (female,
age range: 4 to 6 years old) with CF (all were heterozygous for the
F508del mutation, recruited under the SHIELD (Study of Host
Immunity and Early Lung Disease in Children with Cystic
Fibrosis) Study directed by Dr Paul McNally, National Children’s
Hospital Crumlin, Dublin.
Chemicals
Texas-Red dextran and Calcein AM were purchased from
Biosciences (Biosciences, Invitrogen, molecular probes, Dun
Laoghaire, Ireland). The perfluorocarbon (FC-72), used to prevent
ASL evaporation, was a kind gift from 3M (3M, St Paul, USA).
17b-estradiol (cell culture tested) was purchased from Sigma
(Sigma-Aldrich, Dublin, Ireland). The Chromanol HMR-1556
[(3R,4S)-(+)-N-[3-hydroxy-2,2-dimethyl-6-(4,4,4-trifluorobutoxy)-
chroman-4-yl]-N-methylmethanesulfonamide] is a chromanol
derivate [25] with an increased potency to block KvLQT1/minK
potassium channels, which was kindly provided by Dr. Uwe
Gerlach (Aventis Pharma Deutschland, Frankfurt-am-Main,
Germany). Rottlerin was purchased from Calbiochem (Notting-
ham, UK). The Estrogen Dendrimer Conjugate and its control
molecule, the Empty dendrimer were synthesized as previously
described [26,27], stored in methanol at –20uC and used within 3
months of preparation.
Polarized cell culture
A normal cell line called NuLi-1 (Normal Lung, University of
Iowa), which was derived normal human airway epithelium of
normal genotype, and a CF cell line, called CuFi-1 (CysticFibrosis,
University of Iowa), which was derived from bronchial epithelium
of a homozygous CFTR F508del/F508del individual, were
generous gifts of A. Klingelhutz, P. Karp, and J. Zabner
(University of Iowa, Iowa City, IA) [28]. Cells were initially
grown to confluency in human placental collagen type VI (Sigma-
Aldrich)-coated flasks using Bronchial Epithelium Basal Medium
(BEBM, CloneticsTM, Lonza, Isis, Bray, Ireland) supplemented
with 0.1% human recombinant epidermal growth factor, 0.4%
bovine pituitary extract, 0.1% epinephrine, 0.1% transferrin, 0.1%
insulin, 0.1% retinoic acid, 0.1% hydrocortisone, 0.1% triiodo-
thyronine, and 50 mg/ml gentamicin (GibcoH, Invitrogen, Dun
Laoghaire, Ireland), 0.025 mg/ml penicillin/streptomycin and 1.25
mg/ml FungizoneH Antimycotic (GibcoH). These cell lines were
then grown in a liquid/liquid interface on human placental
collagen type VI millicell hanging cell culture inserts (Millipore,
Billerica, USA) or on Costar Snapwell culture inserts (Corning,
Dublin, Ireland) in BEGM, as previously described [28]. Once
confluence was reached, cells were cultured in a 1:1 ratio of
Dulbecco’s Modified Eagle’s Medium (DMEM) and Ham’s F-12
Medium (Sigma-Aldrich) supplemented with 2 % UltroserG
(Biosciences, Dun Laoghaire, Ireland), 50 units-50 mg/ml penicil-
lin/streptomycin, 50 mg/ml gentamycin and 1.25 mg/ml ampho-
tericin B. After 2 days in this DMEM:Ham’s F12 media, the cells
were cultured at an air/liquid interface (ALI). Transepithelial
electrical resistance (TEER) measurements were taken every 4–5
days using the Epithelial Volt-Ohm Meter (EVOM, World
Precision Instruments, Aston, UK) according to manufacturer’s
instructions and converted to V.cm22 based on surface area of cell
culture insert. Once TEER reached at least 1000 V.cm22
(indicating the formation of a well differentiated epithelium -
approximately 28 days), cells were used for experiments.
Primary cells were obtained from bronchial brushings obtained
in 3 children (female, age range: 4 to 6 years old) with CF (all were
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heterozygous for the F508del mutation). After collection, cells were
washed and seeded in flasks in tobramycin (80 mg/ml, Calbio-
chem, Nottingham, UK) containing BEGM. When cells reached
70% confluence, they were split and seeded onto semi-permeable
support in a mixture (50:50) of tobramycin containing BEGM and
retinoic acid (1 mM, Sigma-Aldrich) containing DMEM. After
approximately 28 days, cells formed a ciliated well-differentiated
polarized epithelium and were used in confocal microscopy
experiments to measure the ASL height.
Airway Surface Liquid height measurement
To allow the measurement of a red stained, stabilized ASL, the
well-differentiated epithelium was covered with 8 ml of Texas-Red
coupled to dextran (2 mg/ml; Invitrogen, Dun Laoghaire, Ireland)
24h before the experiment, as previously described [29]. The cells
were stained with 5 mg/ml Calcein-AM (Molecular Probes, Bio-
Sciences, Dun Laoghaire, Ireland) for 2h before the experiment,
and in order to prevent ASL evaporation during the experiment,
the apical surface was covered with 500 ml of perfluorocarbon (FC-
72). The ASL height was measured by laser scanning confocal
microscopy using a Zeiss LSM 510 (Carl Zeiss MicroImaging
GmbH, Germany). Calcein green has an excitation wavelength of
488 nm and Texas-red, of 543 nm. The ASL depth was measured
by taking the average XZ height of the Texas Red-stained layer at
nine points in at least five different fields over the surface of the
monolayer.
Electrophysiological Measurements
NuLi-1 and CuFi-1 cell monolayers were mounted in Ussing
chambers (aperture 1.12 cm2) and bathed in oxygenated (95%
O2/5% CO2) Krebs solution [comprised of (mM): 140 Na
+, 5.2




22, and 10 glucose)] at 37uC. Monolayers were voltage-
clamped to 0 mV and monitored for changes in short-circuit
current (DIsc) using a VCC MC8 voltage-clamp (Physiological
Instruments, San Diego, CA, USA). The transepithelial short-
circuit current (Isc) was recorded using Ag-AgCl electrodes in 3 M
KCl agar bridges, as previously described, and the A&A software
(Warner Instruments LLC, Hamden). The cells were allowed to
equilibrate for 15–20 minutes before the experiments were
performed. Results were normalized to an area of 1 cm2 and
expressed as Isc ( mAmp.cm22).
In these conditions, NuLi-1 and CuFi-1 cell monolayers were
first treated basolaterally with E2 for 30 minutes. Then they were
treated apically with amiloride, allowing the measurement of
ENaC activity (represented as -DIsc(amiloride)). ATP and then
forskolin were added and finally cell monolayers were incubated
basolaterally with bumetanide. Under these conditions, DIsc(bume-
tanide) across NuLi-1 or CuFi-1 monolayers is wholly reflective of
changes in electrogenic Cl2 secretion.
Na+/K+-ATPase activity was measured as described by Lam et
al. [30]. CuFi-1 monolayers were bathed bilaterally in low-Na+
(25 mM) Krebs solution, where NaCl was substituted with
equimolar N-methyl-d-glucamine (NMDG)-Cl2. Apical mem-
branes were permeabilized with amphotericin B (10 mM) and
ouabain (100 mM) was added basolaterally. Under these condi-
tions (i.e., in the absence of ionic gradients across the
permeabilized monolayer), changes in Isc (-DIsc(ouabain)) are
reflective of electrogenic transport through the Na+/K+-ATPase.
Protein extraction
NuLi-1 and CuFi-1 cell monolayers grown under a thin film at
the air-liquid interface, were washed twice with ice-cold PBS and
lysed (lysis buffer composition: TrisHCl 50 mM, NaCl 150 mM,
NP40 1 %, Glycerol 3 %, EDTA 2 mM, EGTA 2 mM). Lysates
were sonicated (3610s pulses), centrifuged (14 000 rpm, 15 min,
4uC) and pellets were discarded. Protein concentrations were
measured using BioRad protein assay and the supernatants were
stored at –80uC until used for Immunoblotting
Immunoblotting
Samples were normalized for protein content, and 2X gel
loading buffer (Sigma-Aldrich) was added. After heating at 95uC
for 10 min, samples were separated by SDS-PAGE and transferred
to nitrocellulose membranes. Membranes were blocked in 5%
blocking buffer [Bovine Serum Albumin in Tris buffered saline
with 0.1% Tween (TBST)] for 60 min at room temperature,
followed by incubation with primary antibody (phospho-PKCa/
bII, phospho-PKCf/l, phospho-PKCd/h, total PKCa/bII, total
PKCf/l, total PKCd/h dilution 1/1000 in 5% BSA in 0.1%
TBST – cell signalling or b-actin 1/5000, Sigma-Aldrich)
overnight at 4uC. After washing (46) in TBST, membranes were
incubated with HRP-conjugated secondary antibodies (anti-rabbit
1/10000, Abcam, anti-mouse 1/10000) in 5% blocking buffer for
60 min at room temperature. After further washing (46) in TBST,
immunoreactive proteins were detected by enhanced chemilumi-
nescence (Amersham Biosciences, Little Chalfont, UK).
Statistical analysis
Data shown are means 6 SEM, and the Student paired t-test or
one-way repeated measure ANOVA were used to compare the
means of different treatment groups unless otherwise indicated.
Unpaired t-test and one-way ANOVA were used for the
comparison of NuLi-1 vs. CuFi-1 cells. The difference between
two means was considered to be significant when p,0.05.
Results
Estrogen decreases ASL height in normal and CF
bronchial epithelial cell lines and in CF primary bronchial
epithelial cells
NuLi-1 and CuFi-1 cell monolayers were treated for 30 minutes
with increasing concentrations of 17b-estradiol after the ASL was
stained with TexasRedTM Dextran and epithelial cells were
stained with Calcein Green AM. Under basal conditions, CF
epithelia showed a disrupted and thinner ASL compared to the
non-CF epithelia (Figure 1A). Moreover, at a concentration as low
as 0.1 nM, E2 significantly decreased ASL height in both CF and
non-CF cell lines, and this effect was maximal as increasing E2
concentration did not further lower ASLh (Figure 1B). It is
interesting to note that after treatment with E2, the ASLh in CuFi-
1 cells is still significantly lower than in NuLi-1 cells up to a
concentration of 1 nM of estradiol. These concentrations are the
closest to physiological concentrations of E2. Indeed, it has been
shown that the concentration of estradiol in the plasma of normal
women is less than 2 nM [31]. On average, when treated with
concentrations from 0.1 to 1 nM, the ASLh is 0.960.1 mm lower
in CuFi-1 than in NuLi-1 cells, whereas it is only 0.360.1 mm
lower when the cell monolayers are treated with concentrations
from 3 to 10 nM. (n= 3, p = 0.016).
The effect of E2 on ASL height was confirmed using primary
epithelial cells from bronchial brushings in 3 young CF children
who were heterozygous for the F508del mutation. As shown in
figure 1C, 1 nM E2 strongly decreased the ASL height in the CF
airway epithelium (representative confocal image from patient 2).
Figure 1D summarizes the significant decrease induced by
estrogen on ASL height in the primary cultures from the 3 CF
Estrogen Regulates ASL in CF
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children (control: 7.860.5 mm, E2: 5.860.3 mm, n= 3, paired t-
test, p = 0.008).
Rapid and non-genomic effects of E2 on ASL height
Non-genomic responses to steroid hormones can be discrimi-
nated from genomic actions by their rapid time course and more
precisely by employing certain selective estrogen receptor modu-
lators (SERMS) having pathway selective activity. Estrogen
conjugated to cell-impenetrant macromolecules, such as Bovine
Serum Albumin (E2-BSA), have largely been used for this purpose,
although there have been concern about the efficiency of such
molecules. Indeed, the selected binding site of the estrogen could
interfere with the binding to the receptors and the weak chemical
stability could lead to the release of small fragments of active
molecules [32,33]. Here, we have used a novel SERM, the
Estrogen Dendrimer Conjugate (EDC), to selectively activate the
extranuclear estrogen receptor. This compound is composed of a
dendrimer molecule (PAMAM) that is coupled to ,20 molecules
of estrogen, allowing the EDC to interact at the plasma membrane
and enter the cytoplasm but not penetrate the nuclear membrane,
thus discriminating the genomic from the non-genomic effects of
E2 [26,34]. Both CF and non-CF cell lines were treated for 30
minutes either with E2, EDC or the empty dendrimer PAMAM
molecule (that is not coupled to E2) as a control. After 30 minutes
treatment, ASL height was significantly decreased in both cell lines
by E2 (by 22.6%65.1 in CuFi-1, p = 0.019, n= 12 and
25.5%65.4 in NuLi-1 cells, p = 0.001, n = 6) and EDC (by
14.9%67.4 in CuFi-1, p = 0.004, n$5 and 35.9%63.4 in NuLi-1
cells, p,0.001, n$4) at 1 nM (E2 equivalent concentration), but
not by the empty dendrimer (D) (Figure 2). This result indicates
that E2 regulates ASL height rapidly in a non-genomic manner.
Estrogen effects on Na+ absorption and Cl2 secretion in
non-CF epithelial monolayers and consequences for ASL
height
The ability of estrogen to reduce ASL height implies an effect
on transepithelial ion transport and obligatory water flow. We
investigated the ion transporters potentially targeted by estrogen
using transporter inhibitors and measuring their effects in
combination with estrogen on ASL height and short-circuit
current. In NuLi-1 cells, amiloride sensitive current is higher than
in CuFi-1 cells (NuLi-1: 19.161.5 mAmp.cm22, CuFi-1:
12.861.0 mAmp.cm22, p,0.001, n$17) (Figure S1A). But in
these non-CF cells it represents only 70.063.7% of the total
current whereas amiloride-sensitive current represents 86.962.2%
of the total current in CuFi-1 cells (p,0.001, n$17) (Figure S1B).
The effect of estrogen on different ion transporters was tested in
Ussing chamber experiments (Figure 3A). In short-circuit
Figure 1. Concentration-dependence of 17b-estradiol effects
on ASL height in NuLi-1 and CuFi-1 epithelial monolayers and
the effect of 1 nM E2 on ASL height of primary CF bronchial
epithelial cells. Epithelial cells were stained with Calcein Green and
the ASL stained using dextran conjugated Texas RedTM fluorochrome 24
h before estrogen treatment. Panel A shows representative z-plane
sections of NuLi-1 (left) and CuFi-1 (right) cells under basal conditions
(top) and after 30 mins treatment with 1 nM E2 (bottom). Mean
changes in ASL height in control conditions or following treatment with
different concentrations of estrogen are shown in panel B for NuLi-1
(solid line) and CuFi-1 (dashed line) cells (n$4, Error bars reflect
standard error of the mean, ANOVA, ** p,0.01, *** p,0.001, compared
to control conditions; d p,0.05, dd p,0.01, ddd p,0.001, difference
between NuLi-1 and CuFi-1 cells at the indicated estrogen concentra-
tion, ns: non significant). Representative z-plane sections of CF primary
bronchial epithelial cells under basal conditions (left) and after 30 mins
treatment with 1 nM E2 (right) (panel C) and mean changes in ASL
height in primary bronchial epithelial cells of 3 CF female children
(panel D) (n = 3, paired t-test, ** p,0.01)
doi:10.1371/journal.pone.0078593.g001
Figure 2. Effect of the Estrogen Dendrimer Conjugate on ASL
height. NuLi-1 and CuFi-1 epithelial monolayers were treated with
1 nM E2, or EDC at concentrations providing 1 nM estrogen equiva-
lents, or empty dendrimer at the concentration that matched that in
EDC at a 1 nM estrogen equivalent. Panel A shows typical z-plane
sections in control conditions or after treatment with E2, EDC or the
empty dendrimer (D). The concentrations given for the EDC and the
empty dendrimer are in equivalent E2 concentrations. Panel B shows
the mean changes in ASL height in control conditions or following
exposure to E2, EDC or the empty dendrimer (n$4, Error bars reflect
standard error of the mean, ANOVA, * p,0.05, ** p,0.01).
doi:10.1371/journal.pone.0078593.g002
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conditions, estrogen did not have any effect on amiloride-sensitive
current (Control: amil Isc 12.665.0 mAmp.cm22, E2: amil Isc
11.864.7 mAmp.cm22, p = 0.649, n = 4), (Figure 3B). Moreover,
in open-circuit conditions, NuLi-1 cells treated with amiloride do
not show an increase in ASLh (Figure 3C) (control: ASLh
6.460.4 mm, amiloride: ASLh 6.160.2 mm, p= 0.484, n = 4).
This shows that even though amiloride-sensitive current represents
70% of the total current in NuLi-1 cells, the inhibition of ENaC by
amiloride does not modulate ASLh in open-circuit conditions and
that non-CF cells are able to finely regulate their ASLh using other
pathways and ion transporters. The addition of amiloride after
treatment of NuLi-1 cells with E2 shows that the inhibition of
ENaC allows recovery of a similar ASLh as in control conditions
(control: ASLh 6.460.4 mm, E2 + amiloride: ASLh 6.260.2 mm,
p= 0.356, n = 4) (Figure 3C). These results strongly suggest that
E2 targets other ion transporters besides ENaC to regulate ASLh
in non-CF cells.
Cl2 secretion plays a major role in generating and regulating
the ASL height and transepithelial ionic current in NuLi-1 cells. In
the non-CF cell line, the application of the NKCC1 inhibitor,
bumetanide, to the basolateral side of NuLi-1 monolayers led to a
significant decrease in ASL height (Control: ASLh 6.260.2 mm,
Bumetanide: ASLh 4.860.1 mm, p,0.001, n = 5). Pretreatment of
the non-CF cell monolayers with E2 had no additive effect on ASL
height (E2 + Bumetanide: ASLh 4.760.2 mm), indicating that the
hormone reduces ASL via inhibition of Cl2 secretion in the non-
CF monolayer (Figure 3D). To confirm this result, NuLi-1
monolayers were mounted in Ussing chambers and Cl2 secretion
was measured as the bumetanide-sensitive short-circuit current.
Following treatment with E2, the bumetanide-sensitive Isc was
significantly reduced by 21.067.7 % (p,0.05, n= 5) compared to
non-treated NuLi-1 cells (Figure 3E).
Transepithelial chloride secretion was stimulated by the cAMP
agonist forskolin in NuLi-1 monolayers (Figure 3A). This is a
typical Isc response in CFTR-expressing secretory epithelia. We
tested the effect of estrogen and forskolin on ASL height. The ASL
height in NuLi-1 monolayers was significantly increased after 30
minutes forskolin treatment from 6.760.5 mm to 7.660.5 mm, n
= 4, p,0.05 (Figure 3F). Pre-treatment of NuLi-1 monolayers
with estrogen (1 nM) for 30 mins prior to forskolin, prevented the
stimulatory effect of this cAMP agonist on ASL height (E2 alone:
ASLh 5.660.3 mm, FSK alone: ASLh 7.660.5 mm, E2 + FSK:
ASLh 6.160.8 mm, n = 4, p,0.01), (Figure 3F).
Estrogen effects on Na+ absorption and Cl2 secretion in
CF epithelial monolayers and consequences for ASL
height
CF cells secrete very low or no Cl2. In short-circuit conditions,
the bumetanide-sensitive current is 0.060.1 mAmp.cm22 (Figure
S1A and Figure 4A) and represents 1.063.0% of the total current,
whereas it represents 38.462.5% of the forskolin-induced current
in non-CF cells (p,0.001, n$8) (Figure S1B). Although there is no
bumetanide-sensitive current in CuFi-1 cells in short-circuit
conditions, bumetanide alone is able to significantly decrease
ASLh in open-circuit conditions (Control: ASLh 5.160.1 mm,
bumetanide: ASLh 4.260.3 mm, p=0.005, n= 5) (Figure 4B).
Bumetanide is a specific inhibitor for the Na+-K+-2Cl2 cotran-
sporter (NKCC1), and therefore it also inhibits Na+ entry in the
cells. As the Na+/K+ATPase is constitutively active to maintain the
membrane potential difference, the inhibition of NKCC1 might
lead to an increase in Na+ absorption via ENaC, explaining the
decrease in ASLh after bumetanide treatment in CuFi-1 cells. E2
addition prior to bumetanide treatment does not show an additive
Figure 3. E2 inhibits Cl2 secretion in NuLi-1 cells. NuLi-1 cells
were cultured on collagen-coated culture inserts. The monolayers were
then allowed to reach a transepithelial resistance of 1,000 V.cm22 or
above prior the experiment. A. When mounted in the Ussing chambers,
the cells were allowed to stabilize and were then treated basolaterally
with E2. The changes in short-circuit current were then measured in
response to amiloride (10 mM), ATP (100 mM), forskolin (10 mM) and
bumetanide (10 mM). Typical traces of Isc in control and E2 treated
NuLi-1 cells are shown. B. Summary of the amiloride short circuit current
in control and E2 treated cells. Panel C shows ASLh measurement in
NuLi-1 in response to estrogen and ENaC inhibition. NuLi-1 monolayers
were treated with E2 (1 nM), Amiloride (Am, 300 mM) or pretreated with
estrogen and then treated with amiloride (E2 + Am) (n$3, error bars
reflect standard error of the mean, ANOVA, ** p,0.01, *** p,0.001).
Panels D and F show ASLh measurement in NuLi-1 epithelial cells after
treatment with (D) E2 (30 min, 1 nM), Bumetanide (Bum, 30 min, 10 mM)
or pretreated with E2 and then treated with Bumetanide (E2 + Bum) or
(F) E2 (30 min, 1 nM), Forskolin (FSK, 30 min, 10 mM) or pretreated with
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effect (ASLh: E2: 4.560.1 mm, E2 + Bumetanide: 4.360.3 mm, ns,
n = 5), suggesting that E2 could target ENaC (Figure 4B).
CuFi-1 cell monolayers displayed an increased amiloride-
sensitive current after treatment with E2 for 30 min (Control:
Amiloride Isc 8.461.7 mAmp.cm22, E2: Amiloride Isc
10.762 mAmp.cm22, n = 7, p,0.05, (Figure 4C). The conse-
quences for ASL height regulation of estrogen stimulation of Na+
absorption via ENaC were tested. As reported above, 1 nM E2
significantly decreased ASL height (from Control ASLh
5.460.2 mm to E2 4.860.2 mm, n = 6, p,0.001), whereas
amiloride, diluted in the perfluorocarbon and applied on the
apical surface of CuFi-1 monolayers, increased the ASL height
(Control: 5.460.2 mm, Amiloride: 6.860.3 mm, n = 6, p,0.05)
(Figure 4D). These results indicate that estrogen and amiloride
have opposite effects on ENaC activity, resulting in opposite effects
on ASL height. This conclusion is reinforced by the observation
that estrogen pretreatment of CuFi-1 monolayers prevented the
amiloride-induced increase in ASL height (Amiloride: ASLh
6.860.3 mm, E2 + Amiloride: ASLh 5.560.4 mm, n = 6,
p,0.05), (Figure 4D).
Estrogen effects on Na+/K+ ATPase in CF epithelial
monolayers
Although the amiloride experiments indicate a stimulatory
effect of estrogen on ENaC, the transepithelial sodium reabsorp-
tion is a two-step process, and an effect of E2 on the basolateral
Na+/K+ pump may also contribute to an enhanced sodium
uptake. We investigated the effect of E2 on the basolateral
membrane ionic current produced by Na+/K+ ATPase activity in
CuFi-1 monolayers mounted in Ussing chambers. As described in
Methods, the specific current generated by the Na+/K+ ATPase
pump was extracted from the total current flowing across the
basolateral cell membrane by first permeabilizing the apical
membrane with amphotericin B and then measuring the ouabain-
sensitive short-circuit current. Exposure to estrogen caused a rapid
increase (46.3%) in the ouabain-sensitive current (Control:
8.062.3 mAmp.cm22 to E2 11.762.6 mAmp.cm22, n = 4,
p,0.05), (Figure 4E). This result implies that the stimulatory
effect of estrogen on transepithelial sodium reabsorption results
from a combination of enhanced ENaC and Na+/K+ ATPase
activity.
Estrogen effects on K+ recycling in CF and non-CF
epithelial monolayers and consequences for ASL height
It has been shown that K+ recycling at the basolateral
membrane of epithelia regulates Cl2 secretion and Na+ absorp-
tion. The Na+/K+ ATPase transports K+ ions against an electrical
and chemical gradient into the cell. Potassium is thus accumulated
in the cell above its electrochemical equilibrium and is recycled
across the basolateral cell membrane via K+ channels. The
electrogenic leak of K+ maintains a membrane potential hyper-
polarised in relation to the equilibrium potential for Cl2 and Na+,
and thus maintains the electrical driving force for Cl2 secretion
and Na+ absorption. Since we showed that E2 inhibited Cl2
secretion in NuLi-1 cells and activated Na+ absorption in CuFi-1
cells, the involvement of K+ channels in the regulation of ASL
height and its response to estrogen were investigated. As a first
E2 and then treated with Forskolin (E2 + FSK) (n$5, Error bars reflect
standard error of the mean, ANOVA, * p,0.05, ** p,0.01, *** p,0.001).
Panel E shows bumetanide-sensitive current in NuLi-1 cells treated with
E2 or with vehicle. Bumetanide was added after 30 minutes (n$5, Error
bars reflect standard error of the mean, Student’s t test, * p,0.05).
doi:10.1371/journal.pone.0078593.g003
Figure 4. E2 increases Na+ absorption in CuFi-1 cells. CuFi-1 cells
were cultured on collagen-coated culture inserts. The monolayers were
allowed to reach a transepithelial resistance of 1,000 V.cm22 or above
prior the experiment. A. In the Ussing chambers, the cells were allowed
to stabilize and were then treated basolaterally with E2. The changes in
short-circuit current were measured in response to amiloride (10 mM),
ATP (100 mM), forskolin (10 mM) and bumetanide (10 mM). Typical traces
of Isc in vehicle and E2 treated CuFi-1 cells are shown. B. ASLh was
measured in CuFi-1 cells in response to estrogen and NKCC1 inhibition.
CuFi-1 monolayers were treated with E2 (1 nM), Bumetanide (Bum,
10 mM) or pretreated with estrogen before bumetanide was added (E2
+ Bum) (n = 5, error bars reflect standard error of the mean, ANOVA, *
p,0.05, ** p,0.01, ns: non significant). C. Amiloride-sensitive current in
CuFi-1 cells treated with E2 or vehicle. Amiloride was added after 30
minutes (n = 6, Error bars reflect standard error of the mean, Student’s t
test, * p,0.05). D. ASLh measurement in CuFi-1 cells after treatment
with E2 (30 min, 1 nM), Amiloride (Amil, 20 min, 300 mM) or pretreated
with E2 and then treated with Amiloride (E2 + Amil) (n = 7, Error bars
reflect standard error of the mean, ANOVA, * p,0.05, *** p,0.001). F.
Ouabain–sensitive current in CuFi-1 cells mounted in Ussing chambers
and bathed in modified low Na+ Krebs buffer in which NaCl was
replaced by NMDG-Cl2. After the current stabilised, the apical
membrane was permeabilized and the cells were treated with E2 or
with vehicle and Ouabain (100 mM) was added to the basolateral
chamber after 30 minutes (n = 4, Error bars reflect standard error of the
mean, Student’s t test, * p,0.05).
doi:10.1371/journal.pone.0078593.g004
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approach, the total basolateral K+ conductance was reduced using
a cocktail of K+ channel blockers containing BaCl2 (10 mM) and
tetraethylammonium (TEA 1 mM). This combination of K+
channel blockers caused a significant decrease in ASL height in
both NuLi-1 monolayers (from 7.560.7 mm to 5.860.4 mm, n=5,
p,0.05) and CuFi-1 monolayers (from 5.460.1 mm to
4.460.2 mm, n= 5, p,0.01). Subsequent estrogen addition had
no additive effect on ASL height (E2 + BaCl2/TEA: 5.760.5 mm
and 4.560.1 mm in NuLi-1 and CuFi-1, respectively), (Figure 5A).
These results are highly suggestive that E2 also targets K+
recycling to decrease ASL height. We have previously reported
that in distal colonic epithelium, Cl2 secretion is inhibited by E2
via the inhibition of the KCNQ1 potassium channel. Therefore,
we examined if this channel was targeted by E2 in the airway
epithelia by testing the effect of a KCNQ1 specific inhibitor,
chromanol HMR1556, on ASL height. Chromanol HMR1556
(1 mM) significantly decreased ASL height in CuFi-1 monolayers
(from 5.660.2 mm to 4.560.3 mm, n= 4, p,0.01) and in NuLi-1
monolayers (from 6.560.3 mm to 4.760.6 mm, n=4, p,0.01),
(Figure 5B). Subsequent treatment with estrogen had no additive
effect, indicating that the KCNQ1 potassium channel is a target of
E2 in bronchial epithelium as it is in colonic epithelium. Inhibition
of KCNQ1 channels by estrogen will reduce the electrical driving
force for Cl2 efflux across the apical membrane and may be an
additional factor in mediating the E2 down-regulating effect on
ASL height.
Estrogen modulation of protein kinase activity in NuLi-1
and CuFi-1 cells
Our previous studies have shown the involvement of protein
kinase C delta (PKCd) activation in the regulation of intestinal ion
transport by estrogen [13]. The effect of E2 on the activation of
different PKC isoforms was assessed by Western blotting. As
shown on Figure 6A and B, E2 had no effect on the
phosphorylation of PKCa/bII and PKCf/l isoforms either in
non-CF or in CF cells. However, E2 induced an increase in PKC
d/h phosphorylation in NuLi-1 and CuFi-1 cells (Figure 6C) and
this increase is significant in both cell lines after a 30 minutes
treatment (Figure 6D). There was no effect of E2 treatment on the
expression of these kinases (data not shown). To confirm the
involvement of PKCd/h in the effect of E2 on ASL height, we
tested a PKCd specific inhibitor, rottlerin (5 mM), in ASL height
measurement experiments. This inhibitor, alone, had no effect on
ASL height in CF and non-CF cells (CF Control: 5.360.1 mm,
rottlerin: 5.460.3 mm p.0.05; non-CF control: 7.960.23 mm,
rottlerin: 8.260.7 mm, p.0.05, data not shown). However, a pre-
treatment of CuFi-1 and NuLi-1 cells with rottlerin prior to the
treatment with E2, prevented the E2-induced decrease in ASL
height in CF CuFi-1 cells (from E2: 4.560.2 mm to rottlerin + E2:
5.760.2 mm, n = 5 p, 0.05) without affecting the E2-induced
decrease in ASL height in non-CF NuLi-1 cells (Figure 6E).
Discussion
Female patients with CF have a worse prognosis than CF males,
and many studies point towards a role for estrogen in the aetiology
of this CF ‘gender gap’. It has been shown since the 1990s that
estrogen exacerbates lung infection in CF. Estrogen increases the
severity of Pseudomonas aeruginosa-induced pneumonia in CF mice
[24] as well as promoting the conversion of this bacteria to a
mucoid form in women with CF [22]. The airways in CF females
are colonized earlier by pathogens such as Burkholderia cepacia, with
a 2.4-increased risk compared to men with CF [35]. Moreover, in
a study from 2010, Chotirmall et al. showed that estrogen inhibited
the NF-kB signalling pathway, leading to a decrease in IL-8
secretion in CF bronchial epithelial cells. The combined effect of
E2 on infection and inflammation was correlated with increased
pulmonary exacerbations in female CF patients in high estrogen
states (estrous mid-cycle) [21]. The CF gender gap tends to
diminish with age, most likely related to decreased estrogen
production as patients live longer and enter the menopause but
also as a result of improved physiotherapy, more aggressive
antibiotics and advanced care after lung transplant [36]. However,
in spite of improved and aggressive therapies, females with CF still
scored worse than age-matched CF males on quality of life studies
[37], and they show more acute lung exacerbations [38]. It is
therefore important to understand the basic cellular and molecular
Figure 5. E2 inhibits K+ recycling in normal and CF bronchial
cell lines. A. NuLi-1 (grey bars) and CuFi-1 (white bars) epithelial
monolayers were stained with Calcein Green and ASL was stained with
dextran conjugated to Texas RedTM fluorochrome and ASL height was
measured after treatment with E2 (30 min, 1 nM), and a cocktail of BaCl2
and TEA to inhibit potassium channels (B/T 30 min, BaCl2 10 mM, TEA
1 mM) or pretreated with E2 and then treated with the K+ channels
cocktail inhibitor (E2 + B/T) (n = 5, Error bars reflect standard error of the
mean, ANOVA, * p,0.05, ** p,0.01). B. NuLi-1 (grey bars) and CuFi-1
(white bars) epithelial monolayers were treated with E2 (30 min, 1 nM),
and the KCNQ1 channel specific inhibitor HMR1556 (HMR, 30 min,
1 mM) or pretreated with E2 and then treated with HMR1556 (E2 + HMR)
(n$3, Error bars reflect standard error of the mean, ANOVA, ** p,0.01).
doi:10.1371/journal.pone.0078593.g005
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mechanisms by which estrogen can modulate lung function in
women with CF so that adapted therapies can be implemented. In
this study, we evaluated the role of estrogen on ASL dynamics and
ion transport in airway epithelium. We found that physiological
concentrations of estrogen decreased ASL height in both non-CF
and CF bronchial epithelial cell lines but that it is still higher in
non-CF cells than in CF cells. Estrogen decreased significantly the
ASLh in primary epithelial cells grown from bronchial brushings
obtained from CF children,. A previous study reported similar
effects of E2 to reduce ASL in CF and non-CF airway cells via an
inhibition of Ca2+ signalling [19]. Although the E2-induced
decrease in ASLh might seem modest, the height of the ASL in
normal human bronchial epithelium has been shown to be in the
range of 7 to 9 mm and this height is critical for efficient
mucociliary clearance. Indeed, the size of the outstretched cilia is
approximately 7 mm and it has been shown that mucociliary
clearance is impaired when ASL height is decreased [39]. In CF
patients, the height of the airway surface liquid is already
decreased and characterised by a reduced mucociliary clearance.
During the menstrual cycle, E2 can reach concentrations of 1–
1.5 nM at the pre-ovulation peak. Therefore, the 1 nM E2-
induced decrease in ASL height from 5.660.1 mm to 4.460.3 mm
in the CF cells (Figure 1B) would substantially further impair
mucociliary clearance and could, at least in part, explain the
increase in exacerbations observed in women with CF at this phase
of the menstrual cycle [22]. Our study focused on the determi-
nation of the ion transporter targets, and we showed that E2
decreased ASL height in non-CF cells through the inhibition of
cAMP mediated Cl2 secretion, indicating CFTR as the target of
E2, which is consistent with previous studies showing the
inhibition of this Cl2 channel after exposure to E2 [14]. It has
also been shown that estrogen can regulate the expression of
CFTR in the female reproductive tract [40] and affect its
expression on developing fetal rat lung epithelium [41]. The effect
of estrogen on CFTR is supported by the abolition of the effect of
E2 in decreasing ASL in non-CF cells after increasing the
intracellular levels of cAMP using forskolin (an activator of the
enzyme adenylyl cyclase).
In CF cells, in which cAMP-activated Cl2 secretion is absent,
the effect of estrogen to decrease the ASL height was mediated by
enhanced sodium absorption. The evidence points to a rapid
estrogen activation of ENaC as well as the Na+/K+ ATPase
leading to a transepithelial hyperabsorption of Na+. Moreover,
estrogen preincubation prevented the amiloride-induced increase
in ASL height, confirming the involvement of ENaC in the effect
of estrogen on ASL homeostasis. It was shown before that estrogen
upregulates ENaCa and ENaCc subunit mRNA and protein
expression levels in osteoblasts, as well as increasing ENaC current
in these cells [42]. In the lung, Laube et al. reported recently that
estrogen increased Na+ transport in alveolar cells through the
Figure 6. E2-induced PKCd activation is responsible for the ASL height decrease in CuFi-1 cells. NuLi-1 (grey bars) and CuFi-1 (white bars)
cells were treated basolaterally with E2 (1 nM) for 30 mins. After hormone treatment, cells were washed and total protein extracts were prepared in
order to measure the level of phosphorylation of PKCa/bII and PKCf/l by immunoblot. Representative Western blots are shown in panel A and
densitometric quantitation of phospho-PKCa/bII / b-actin and phospho-PKCf/l / b-actin are shown in panel B (n = 4, Error bars reflect standard error
of the mean, Student’s t-test). B. NuLi-1 and CuFi-1 cells were treated basolaterally with E2 (1 nM) for the indicated times. After treatment, cells were
washed and total protein extracts were prepared in order to measure the level of phosphorylation of PKCd/h. Representative images are shown in
panel C and mean phosphorylation state of PKCd/h changes in control conditions, or following treatment with estrogen at different time points, are
shown in panel D (n$4, Error bars reflect standard error of the mean, ANOVA, * p,0.05). E. ASL height was measured in CuFi-1 (white bars) and NuLi-
1 (grey bars) monolayers in response to estrogen and PKCd inhibition. NuLi-1 and CuFi-1 monolayers were treated with E2 (1 nM) or pretreated with
rottlerin (5 mM) and then treated with E2 (n = 5, Error bars reflect standard error of the mean, ANOVA, * p,0.05).
doi:10.1371/journal.pone.0078593.g006
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upregulation of the expression of ENaC and Na+/K+ATPase [20].
Taken together with our results, these data show that Na+
transport is an important target for estrogen regulation of fluid
homeostasis in the lung. In our study, we also showed that estrogen
exposure of CF and non-CF bronchial epithelial cells produced an
increase in PKCd/h activation and that the specific inhibition of
PKCd prevents the effect of estrogen on ASL homeostasis in the
CF cells. Although an increase in PKCd/h phosphorylation was
observed in non-CF cells following treatment with E2, rottlerin did
not prevent E2-induced ASLh decrease in these cells, showing that
this kinase is either not involved in the modulation of ion transport
by E2 in non-CF cells or that E2 activates alternative signalling
pathways that could compensate for the effect of PKCd activation
on ASLh. The regulation of Na+ transport by PKC isozymes has
been shown in different studies. For example, estrogen produced a
50% inhibition of 22Na+ uptake in pig kidney epithelial LLC-PK1
cells after PMA (PKC activator) treatment [43]. In the alveoli, it
has been shown that PKC is involved in ENaC-mediated lung
liquid regulation [44]. However, to our knowledge, no report has
shown that the PKCd isoform could regulate fluid absorption
through the bronchial epithelia. Our data also demontrate an
effect of E2 on the activity of Na+/K+ATPase, which may be
transduced via PKCd. In a recent study, Li et al. showed that
estrogen regulates the expression of N-myc downstream-regulated
gene 2 (NDRG2), a protein which can interact with the b1 subunit
of the Na+/K+ATPase, stabilize it and thus increase the Na+/K+
ATPase-mediated Na+ transport [45]. Moreover, the PKCh
isoform, which displays the highest homology to PKCd, is able
to phosphorylate NDRG2 in C2C12 skeletal muscle cells [46].
The similarity between E2 effects on Cl2 secretion in distal colon
[9] and here in normal bronchial epithelium points to a common
signalling pathway (PKA) and ion channel target (KCNQ1). In CF
cells, the signalling pathway involves PKCd similar to female distal
colon [13] and kidney cortical collecting duct cells (Robles,
unpublished). In the latter study, E2 inhibited ENaC via PKCd.
We thus reason that the E2 anti-secretory pro-absorptive responses
are a common feature in epithelial cells of lung, kidney and
intestine [47].
Finally, we reported in this study that E2 acted on the ASL
homeostasis very rapidly (within 30 minutes). The effect of E2 on
ASL height was mimicked when both non-CF and CF cells were
treated with the Estrogen Dendrimer Conjugate (EDC), whereas
the empty dendrimer showed no effect on ASL fluid dynamics.
These results point to a rapid and non-genomic effect of 17b-
estradiol in these bronchial epithelial cells. In the classic genomic
pathway, E2 binds to one of its receptors (ERa or ERb), which
dimerizes and interacts at chromatin gene-regulatory sites, where
this complex recruits co-factors and modulates the transcription of
target genes. These direct transcriptional effects can be measured
after a few hours. The non-genomic pathway, on the other hand,
can involve both types of receptors and in particular a membrane-
associated palmitoylated form of ER [48,49], which induces the up
or down regulation of the activity of cytosolic protein kinases, such
as PKA, PKC or the MAPKinases. This process is rapid (initiated
within seconds) and can regulate ion transport by activating or
inhibiting ion channels. Both isoforms of estrogen receptors (a and
b) can be localized at the plasma membrane and form dimers
[50,51]. Although it is unclear through which extranuclear
receptor, E2 and the EDC might exert their effect on ASLh,
there is growing evidence for the involvement of ERa mediated
actions of the EDC [26,52,53,54]. In CuFi and NuLi cell lines, the
predominant form of ERa is the 36kDa isoform (ER-a36) as
shown on the Western blot (Methods S1- Figure S2A). It has been
shown that ER-a36 mainly localises in the cytoplasm and at the
plasma membrane [55,56]; This ER isoform has been shown to
mediate E2-stimulted PKCd activation in endometrial Ishikawa
cancer cells [57]. Although the localization of this receptor at the
membrane could not be clearly established by immunofluores-
cence (Methods S1) using the same antibody as for the
immunoblots (Methods S1), in CuFi-1 and NuLi-1 cells, ERa is
clearly located to the cytoplasm and treatment with E2 did not
induce its translocation to the nucleus over the 30 minute
observation period (Figure S2B). ERb was detected in both cell
lines (Figure 2C) although its molecular weight (45 kDa) appeared
lower than predicted (59 kDa). There was no difference in the
localization of ERb between CF and non-CF cells and short-term
treatment with estrogen did not affect ERb localization (Figure
S2D). Although our study demonstrates a rapid effect of E2 (and
EDC) on the ASL fluid dynamics, one should not conclude that no
genomic effect is induced during this process. Indeed, it has been
shown ‘non-genomic’ E2 responses both can prime and sustain
transcriptional events through non-nuclear ER responses. Thus,
non-genomic effects of EDC can generate genomic responses [34]
transduced via activation of the transcription factor CREB [54].
Taken together with these studies, our results strongly suggest
that the effect of E2 on ASL fluid dynamics and ion transport is
mediated through an extranuclear ERa. The further investigation
of the involvement of each isoform of the estrogen receptor as well
as the long term effect of E2 and EDC on ASLh and gene
transcription will be beneficial in order to fully understand the
deleterious effect of estrogen in women with CF.
In conclusion, we have identified the ion channel targets for
estrogen in non-CF and CF bronchial epithelia and the
consequences for maintaining airway surface liquid homeostasis.
Moreover, a non-genomic rapid response to estrogen transduced
via extranuclear ER is a component of the deleterious effects of
17b-estradiol in CF lung pathophysiology.
Supporting Information
Figure S1 Contribution of Na+ absorption and Cl2
secretion to total Isc in NuLi-1 and CuFi-1 cells. Amiloride
and bumetanide-sensitive currents were measured in NuLi-1 and
CuFi-1 cell monolayers mounted in Ussing chambers. Panel A
shows amiloride and bumetanide-sensitive currents inmAmp.cm22
(n$8, error bars reflect standard error of the mean, Student’s t-
test, *** p,0.001). Panel B shows the ratio between amiloride-
sensitive current and the total current as a percentage (n$17, error
bars reflect standard error of the mean, Student’s t-test, ***
p,0.001) and the ratio between bumetanide-sensitive current and
the forskolin-induced current as a percentage (n$8, error bars
reflect standard error of the mean, Student’s t-test, *** p,0.001).
(TIF)
Figure S2 Expression pattern and localization of ERa
and ERb isoforms in NuLi-1 and CuFi-1 cells. Panel A
shows the expression of the different isoforms of ERa in NuLi-1
and CuFi-1 cells by Western blot. Panel B shows representative
images of the intracellular localization of ERa before and after 30
mins treatment with 1 nM E2 (n= 4, blue, DAPI; green, ERa; red,
actin). Panel C shows the expression of ERb in NuLi-1 and CuFi-1
cells by Western blot. Panel D shows representative images of the
intracellular localization of ERb before and after 30 mins
treatment with 1 nM E2 (n= 4, blue, DAPI; green, ERb; red,
actin).
(TIF)
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Methods S1 The detailed methods for Estrogen Recep-
tors Immunoblotting and Immunofluoresence detection
are detailed in Methods S1.
(DOC)
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